Copyright
©The Author(s) 2021.
World J Clin Cases. Aug 6, 2021; 9(22): 6357-6379
Published online Aug 6, 2021. doi: 10.12998/wjcc.v9.i22.6357
Published online Aug 6, 2021. doi: 10.12998/wjcc.v9.i22.6357
Ref. | Study design | Patients (n) | Age (yr) mean ± SD/mean | Gender (M/F) | Clinical T stage | Synchronous/metachronous | Tumor location | |||||
Neo chemo | No neo chemo | Neo chemo | No neo chemo | Neo chemo | No neo chemo | Neo chemo | No neo chemo | |||||
Allen et al[58], 2003 | 2003 | Retrospective | 52 | 54 | 59 | 63 | 33/19 | 28/26 | T1/T2/T3/T4 | 52/0 | 54/0 | NR |
Tanaka et al[57], 2003 | 2003 | Prospective | 48 | 23 | 57 (38-69) | 59 (37-79) | 28/20 | 17/6 | NR | 33/15 | 18/5 | a.b |
Aloia et al[56], 2006 | 2006 | Retrospective | 75 | 17 | 57 ± 12 | 60 ± 11.9 | 46/29 | 8/9 | NR | NR | NR | NR |
Hewes et al[54], 2007 | 2007 | Retrospective | 80 | 21 | NR | NR | 40/40 | 11/10 | NR | 25/55 | 7/14 | NR |
Aloysius et al[55], 2007 | 2007 | Prospective | 79 | 25 | 65 (61-72) | 64 (60-70) | 49/30 | 9/16 | NR | NR | NR | NR |
Mehta et al[53], 2008 | 2008 | Retrospective | 130 | 43 | NR | NR | NR | NR | NR | 51/79 | 17/26 | NR |
Tamandl et al[49], 2009 | 2009 | Retrospective | 29 | 41 | 75 ± 3 | 75 ± 3 | 16/13 | 28/13 | T1/T2/T3/T4 | NR | NR | NR |
Boostrom et al[52], 2009 | 2009 | Retrospective | 44 | 55 | 64 | 57.5 | 28/16 | 30/25 | NR | 24/20 | 24/31 | NR |
Lubezky et al[51], 2009 | 2009 | Prospective | 37 | 19 | 63 | 66 | NR | NR | NR | NR | NR | a.b |
Scoggins et al[50], 2009 | 2009 | Retrospective | 112 | 74 | 59 | 68.5 | 67/45 | 38/36 | T1/T2/T3/T4 | 19/93 | 9/65 | a.b.c |
Adam et al[48], 2010 | 2010 | Prospective | 169 | 1302 | NR | NR | 100/69 | 831/471 | NR | NR | NR | a.b.c |
Scartozzi et al[47], 2011 | 2011 | Prospective | 60 | 44 | NR | NR | 23/37 | 23/31 | T1/T2/T3/T4 | NR | NR | NR |
Son et al[46], 2011 | 2011 | Retrospective | 20 | 206 | NR | NR | 15/5 | 134/72 | T1/T2/T3/T4 | 12/8 | 126/80 | a.b |
Cucchetti et al[45], 2011 | 2011 | Prospective | 125 | 117 | 63.9 ±1 0.4 | 64.9 ± 9.8 | 27/20 | 27/20 | T1/T2/T3/T4 | 19/28 | 19/28 | NR |
Spelt et al[43], 2012 | 2012 | Retrospective | 97 | 136 | 64 (33-90) | 66.5 (30-88) | 61/36 | 81/55 | T1/T2/T3/T4 | 65/97 | 70/66 | NR |
Pinto et al[44], 2012 | 2012 | Retrospective | 205 | 205 | 58.9 ± 12 | 61.9 ± 12 | 128/77 | 144/61 | T1/T2/T3/T4 | 123/82 | 105/100 | NR |
Nordlinger et al[59], 2013 | 2013 | RCT | 182 | 182 | 60.7 (9.35) | 62.4 (9.63) | 127/54 | 114/65 | T1/T2/T3/T4 | 61/121 | 67/115 | a.b.c |
Araujo et al[42], 2013 | 2013 | Retrospective | 175 | 236 | 54.8 (47.5-62.3) | 60.9 (51.1-67.6) | 103/72 | 148/88 | NR | NR | NR | a.b |
Oh et al[41], 2013 | 2013 | Prospective | 15 | 15 | 54 | 63 | 12/3 | 11/4 | T2/T3/T4 | NR | NR | a.b |
Scilletta et al[40], 2014 | 2014 | Retrospective | 52 | 129 | 64 ± 13 | 63 ± 9 | 29/23 | 74/55 | NR | NR | NR | a.b.c |
Zhu et al[39], 2014 | 2014 | Retrospective | 121 | 345 | 58.0 (35-72) | 59.0 (28-84) | 81/40 | 213/142 | T1/T2/T3/T4 | NR | NR | a.b |
Bonney et al[37], 2015 | 2015 | Retrospective | 693 | 608 | NR | NR | 418/275 | 370/238 | NR | 693 | 608 | NR |
Schreckenbach et al[36], 2015 | 2015 | Retrospective | 117 | 71 | 61 (35–81) | 69 (34-85) | 86/31 | 74/26 | NR | 87/30 | 26/45 | a. |
Ayez et al[38], 2015 | 2015 | Retrospective | 65 | 154 | 63 (58-70) | 66 (59-72) | 47/18 | 95/59 | NR | 55/10 | 133/21 | NR |
Kim et al[6], 2017 | 2017 | Retrospective | 32 | 32 | 59 ± 10 | 59 ± 8 | 23/9 | 22/10 | T2/T3/T4 | NR | NR | a.b. |
Strowitzki et al[3], 2017 | 2017 | Prospective | 125 | 125 | NR | NR | NR | NR | NR | 69/56 | 69/56 | a.b.c. |
Inoue et al[7], 2018 | 2018 | Retrospective | 61 | 61 | 66 (33-89) | 63 (41-85) | 31/30 | 32/29 | NR | 30/31 | 30/31 | NR |
Kumar et al[8], 2018 | 2018 | Prospective | 176 | 271 | 62 (30-82) | 63 (29-86) | 105/71 | 168/103 | NR | NR | NR | NR |
Makowiec et al[9], 2018 | 2018 | Retrospective | 106 | 228 | 64 (25-80) | 64 (33-87) | 64/42 | 158/70 | NR | 68/38 | 94/134 | a.b |
Hirokawa et al[1], 2019 | 2019 | Prospective | 20 | 117 | 67 (28-76) | 68 (38-89) | 13/7 | 70/47 | T1/T2/T3/T4 | 6/14 | 36/81 | a.b |
Ratti et al[35], 2019 | 2019 | Retrospective | 73 | 73 | 62 (37-84) | 60 (35-86) | 39/34 | 41/32 | T1/T2/T3/T4 | 73/0 | 73/0 | a.b |
Wiseman et al[34], 2019 | 2019 | Retrospective | 1416 | 1416 | 60 ± 7 | 61 ± 12 | 836/580 | 803/613 | NR | NR | NR | NR |
Outcome indicators | No. of study | Patients (n) | HR/OR/SMD (95%CI) | P value | Heterogeneity | ||||
NAC | non-NAC | χ2 | I² | P value | |||||
5-year overall survival | 22 | 2580 | 4218 | 0.49 (0.39-0.61) | P < 0.01 | 14.38 | 0.00% | P = 0.853 | |
5-year disease free survival | 13 | 1643 | 2864 | 0.48 (0.36-0.63) | P < 0.01 | 5.68 | 0.00% | P = 0.931 | |
Duration of surgery | 8 | 1980 | 2396 | 0.41 (0.01-0.82) | P < 0.05 | 172.79 | 95.90% | P = 0.000 | |
Number of liver metastases | 12 | 1017 | 1096 | 0.73 (0.02-1.43) | P < 0.05 | 549.46 | 98.00% | P = 0.000 | |
Blood loss during surgery | 6 | 474 | 646 | 0.53 (-0.05-1.10) | P = 0.072 | 90.12 | 94.50% | P = 0.000 | |
Length of hospital stay (d) | 6 | 605 | 565 | 0.01 (-0.61-1.02) | P = 0.624 | 184.79 | 97.30% | P = 0.000 | |
Size of largest metastases (cm) | 13 | 1226 | 1539 | 0.03 (-0.31-0.30) | P = 0.980 | 168.39 | 92.90% | P = 0.000 | |
Synchronous metastases | 19 | 2355 | 2553 | 1.17 (0.90-1.58) | P = 0.221 | 43.91 | 65.80% | P = 0.000 | |
Major liver resection | 14 | 2780 | 3133 | 1.06 (0.97-1.22) | P = 0.143 | 5.21 | 0.00% | P = 0.970 | |
Lymph node metastasis | 16 | 1523 | 2128 | 1.24 (1.07-1.43) | P < 0.05 | 29.26 | 49.50% | P = 0.013 | |
R0 liver resection | 7 | 723 | 976 | 0.85 (0.61-1.18) | P = 0.336 | 6.29 | 4.60% | P = 0.391 | |
Perioperative complications | 17 | 2886 | 3161 | 1.00 (0.76-1.31) | P = 0.980 | 51.82 | 69.10% | P = 0.000 | |
Bile leakage | 10 | 2244 | 2364 | 1.10 (0.84-1.43) | P = 0.481 | 4.77 | 0.00% | P = 0.782 | |
Surgical site infection | 8 | 2065 | 2056 | 0.94 (0.76-1.16) | P = 0.571 | 9.68 | 27.70% | P = 0.208 | |
Liver failure | 7 | 2025 | 1939 | 1.04 (0.76-1.42) | P = 0.813 | 5.77 | 13.40% | P = 0.329 | |
Blood transfusion | 5 | 1805 | 1710 | 1.07 (0.90-1.29) | P = 0.438 | 5.95 | 32.80% | P = 0.203 |
- Citation: Zhang Y, Ge L, Weng J, Tuo WY, Liu B, Ma SX, Yang KH, Cai H. Neoadjuvant chemotherapy for patients with resectable colorectal cancer liver metastases: A systematic review and meta-analysis. World J Clin Cases 2021; 9(22): 6357-6379
- URL: https://www.wjgnet.com/2307-8960/full/v9/i22/6357.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i22.6357